ABVC BioPharma (ABVC) vs BriaCell Therapeutics (BCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed ABVC BioPharma (ABVC) over the past year, losing 61.7% versus a loss of 67.8%. Over five years, BCTX leads with a -97.0% price change compared with -97.3% for ABVC. BriaCell Therapeutics is the larger company by market cap ($26.7 million vs $23.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABVC | BCTX |
|---|---|---|
| Share price | $0.8663 | $3.06 |
| Market cap | $23.37M | $26.72M |
| 1-day change | -1.56% | -3.32% |
| YTD return | -59.33% | -56.96% |
| 1-year return | -67.80% | -61.75% |
| 5-year return | -97.29% | -97.00% |
| EPS (TTM) | $-0.20 | $-6.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.00K | — |
| Revenue growth (YoY) | -41.91% | — |
| Net income (latest FY) | $-7.91M | $-34.90M |
| Operating margin | -2415.97% | — |
| Net margin | -2671.81% | — |
| 52-week high | $2.87 | $13.09 |
| 52-week low | $0.707 | $2.60 |
| Distance from 52-week high | -69.82% | -76.62% |
| Average volume | 81.92K | 250.81K |
| Shares outstanding | 26.98M | 8.73M |
| Employees | 16 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ABVC BioPharma
ABVC stock →ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
ABVC vs BCTX FAQ
Which is bigger, ABVC BioPharma or BriaCell Therapeutics?
BriaCell Therapeutics (BCTX) is larger, with a market capitalization of $26.72M compared with $23.37M for ABVC BioPharma (ABVC).
Which stock has performed better over the past year, ABVC or BCTX?
BCTX returned -61.75% over the past 12 months, compared with -67.80% for ABVC (price return, excluding dividends). Past performance does not predict future results.
Are ABVC BioPharma and BriaCell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.